Everything you need to know right now about flu and COVID vaccines and the new Hepatitis B guidelines — without all the ...

Moderna shares surge 16% to $50 on five-year melanoma vaccine data showing 49% risk reduction. Analysts target $29.93 despite ...

Sinovac Biotech Ltd. ("SINOVAC" or the "Company"), a leading provider of biopharmaceutical products in China, today announced ...

Amid a surprisingly severe flu season and a Covid-19 resurgence, those highly contagious respiratory illnesses are drawing ...

Pediatric medical professionals are pushing back against new CDC recommendations that implemented major changes to the childhood immunization schedule.

Shares of Moderna ( MRNA +15.65%) popped on Wednesday after the biotech leader announced positive clinical trial results for ...

The positive long-term data represents a significant milestone for Moderna as it works to diversify its revenue beyond COVID-19 vaccines and establish its mRNA platform as a viable cancer treatment ...

In a small clinical trial, customized mRNA vaccines against high-risk skin cancers appeared to reduce the risk of cancer recurrence and death by nearly 50 percent over five years when compared with ...

Moderna stock rose over 7% after the company and Merck said their personalized melanoma vaccine kept working at five years, cutting recurrence or death risk by 49%.

Long-term follow-up data from a phase 2b trial of Moderna and MSD's mRNA-based vaccine against melanoma, intismeran autogene ...

Recent changes to the national immunization schedules have raised questions and caused confusion that could complicate care ...

A coalition of medical groups have expanded an ongoing lawsuit against Health and Human Services (HHS) Secretary Robert F.